Viridian seeks Priority Review for veligrotug, aiming for a potential mid-2026 commercial launch if approved. Global phase 3 ...

(Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism, today announced that the company will host a virtual ...

(Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism, today reported financial results and provided a business ...

For years, protein shakes have been hailed as the magic potion for muscle gain and recovery. Every gym-goer in India seems to ...

A once-daily oral quadruple receptor agonist induced up to 13.8% weight loss at 13 weeks among adults with overweight or ...

Prediabetes burden is rising globally and in India. The latest IDF 2025 Atlas estimated that in 2024, 634.8 million adults (12%) worldwide had IGT, including 89.9 million in India, projected ...

Learn more about whether Protagonist Therapeutics, Inc. or Viridian Therapeutics, Inc. is a better investment based on AAII's ...

Q3 2025 product sales of $22.5 million, representing 129% growth over Q3 2024 and 19th straight quarter of sequential product ...

OTTAWA, ON, Nov. 6, 2025 /CNW/ - The National Aboriginal Capital Corporations Association (NACCA) acknowledges the release of the 2025 Federal Budget and remains steadfast in advancing Indigenous ...

Viridian Therapeutics, Inc. nears profitability and gears up for veligrotug’s 2025 launch. Click here to find out why VRDN stock is a Strong Buy.

Dr. Jerry Mixon explains that andropause affects men's energy, mood and confidence as testosterone declines. Sponsored by ...